Cure CMT
Cure CMT
Cure CMT and Bexion Pharmaceuticals announced an investment from Cure CMT to support the continued development of BXQ‑350 in metastatic colorectal cancer (mCRC) and chemotherapy‑induced peripheral neuropathy (CIPN), two areas of significant unmet medical need.
In mCRC, BXQ‑350 has demonstrated preliminary clinical activity and, in combination with front‑line standard‑of‑care FOLFOX, met the protocol‑prespecified objective response rate (ORR) criteria required to support advancement to the next stage of study. Ongoing development has been informed by feedback from key opinion leaders in the field.
BXQ‑350 is also being evaluated in CIPN, where an exploratory Phase 1 clinical study in 21 patients observed statistical separation from placebo. CIPN remains a common and sometimes debilitating complication of chemotherapy that can lead to dose reductions or early treatment discontinuation and negatively impact quality of life. The investment is intended to support further clinical evaluation of BXQ‑350 and reflects a shared commitment to advancing therapies for serious diseases with limited treatment options.
“BXQ‑350 continues to show promising progress in areas of significant unmet need,” said Jim Beach, Chief Executive Officer of Bexion Pharmaceuticals. “In metastatic colorectal cancer, meeting a predefined milestone in a difficult‑to‑treat patient population represents an encouraging step forward for the program, while its potential application in CIPN highlights a differentiated opportunity to address treatment‑related burden.”
“For patients and families, peripheral neuropathy can be one of the most life‑altering consequences of cancer treatment,” said Pat Livney, Founder, CEO, and Chairman of Cure CMT. “The possibility that BXQ‑350 may address cancer while also mitigating nerve damage is central to why Cure CMT is proud to support this work.”
About Cure CMT
Cure CMT is a patient‑driven organization dedicated to improving outcomes for people affected by peripheral nerve disorders and supporting the development of therapies with the potential to meaningfully improve patients’ lives.
About Bexion Pharmaceuticals
Bexion Pharmaceuticals is a clinical‑stage biopharmaceutical company advancing BXQ‑350, an investigational therapeutic candidate in development for oncology and neuropathy‑related indications.
About BXQ‑350
BXQ‑350 is an investigational product that has not been approved by the U.S. Food and Drug Administration or any other regulatory authority.
Forward-Looking Statements
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause Bexion’s actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. Bexion has in some cases identified forward-looking statements by using words such as “anticipates,” “believes,” “hopes,” “estimates,” “looks,” “expects,” “plans,” “intends,” “goal,” “potential,” “may,” “suggest,” and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are Bexion’s need for, and the availability of, substantial capital in the future to fund its operations and research and development; the fact that Bexion’s compounds may not successfully complete pre-clinical or clinical testing or be granted regulatory approval to be sold and marketed in the United States or elsewhere. You should not place undue reliance on any forward-looking statements, and Bexion explicitly disclaims any obligation to update any forward-looking statements.